<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Luye Pharma Group Ltd — News on 6ix</title>
    <link>https://6ix.com/company/luye-pharma-group-ltd</link>
    <description>Latest news and press releases for Luye Pharma Group Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Sun, 03 Aug 2025 10:23:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/luye-pharma-group-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma&apos;s Investigational Antidepressant Targeting NET/DAT/GABAAR</title>
      <link>https://6ix.com/company/luye-pharma-group-ltd/news/first-subject-enrolled-in-phase-1-clinical-trial-for-luye-pharmas-investigational-antidepressant-targeting-netdatgabaar</link>
      <guid isPermaLink="true">https://6ix.com/company/luye-pharma-group-ltd/news/first-subject-enrolled-in-phase-1-clinical-trial-for-luye-pharmas-investigational-antidepressant-targeting-netdatgabaar</guid>
      <pubDate>Sun, 03 Aug 2025 10:23:00 GMT</pubDate>
      <description>Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China&apos;s Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NET), the dopamine transporter (DAT), and a gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), intended for the treatment of Major Depressive Disorder (MDD).</description>
    </item>
  </channel>
</rss>